Global Branded Generics Industry to Achieve a Striking 8.6% CAGR, Envisioning US$ 747.2 Million by 2033 | FMI

The Global Branded Generics Industry is gearing up for a monumental surge, as projected by industry experts. With an estimated value of US$ 327.8 million in 2023, the sector is set to witness an exceptional compound annual growth rate (CAGR) of 8.6%, soaring to an impressive US$ 747.2 million by 2033.

This exponential growth can be attributed to several key factors, including the expiration of patents for numerous blockbuster drugs and the concurrent rise in chronic illnesses worldwide. The Global Branded Generics Industry is capitalizing on the increasing demand for affordable healthcare, making significant strides in market expansion.

Request a Sample of this Report
https://www.futuremarketinsights.com/reports/sample/rep-gb-1260

Since branded generics are free from patenting, companies are investing handsome amounts on this drug category. The market is set to reach a valuation of around 283.2 Bn in 2021, with top players in tier-1 accounting for 20%-25% market share.

The entry of new players, simple market authorization procedures, greater profit margin and off-invoice discounts will expand the Global Branded Generics Industry during the forecast period.

As per the FMI’s analysis, despite the slight setback due to the pandemic, the Global Branded Generics Industry registered year-on-year (Y-o-Y) growth at 4.9% CAGR during 2020-2021.

“Rising demand for branded generics across both developing and developed economies along with high penetration of pharmaceutical industry will offer lucrative growth opportunities for the branded generics manufacturers during the forecast period” says the FMI analyst.

Key Takeaways from FMI’s Global Branded Generics Industry Study

• China and India are spearheading the growth of Asia Pacific market spurred by the increasing adoption of branded generics by large-scale pharmacy chains in the emerging economies
• The U.S. will lead the North America’s branded generics market, registering a growth at 3.83% CAGR during the forecast period.
• The market in India is expected to offer lucrative growth opportunities to branded generics manufacturers backed the expansion of pharmaceutical industry
• In terms of therapeutic application, cardiovascular diseases and diabetes are expected to account for considerable market share
• Oral solid dose pharmaceutical formulation continues to be highly preferred among patients. The oral segment accounts for over 55% share of the global branded generics market.

Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1260

Global Branded Generics Industry Competitive Landscape

Teva, Abbott Laboratories, Novartis, Mylan, and Pfizer are some prominent players operating in the Global Branded Generics Industry cumulatively hold around 20-25% market share.

Key players operating in branded generic market are focusing on expanding their business in emerging markets. They are adopting various organic and inorganic growth strategies such as mergers and acquisitions, advanced product development and collaborations to gain a competitive edge in the market.

• In October 2020, Glenmark Pharmaceuticals introduces NINDANIB (Nintedanib) for the treatment of pulmonary fibrosis in India. Glenmark has been amongst the first to launch the branded generic version at an affordable cost for the treatment of pulmonary fibrosis in India.

Global Branded Generics Industry by Category Therapeutic Application:

• Oncology
• Cardiovascular Diseases
• Diabetes
• Neurology
• Gastrointestinal Diseases
• Dermatology Diseases
• Analgesics and Anti-inflammatory
• Others

Drug Class:

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid Lowering Drugs
• Anti-Depressants
• Anti-Psychotics
• Anti-Epileptics
• Others

Formulation Type:

• Oral
• Parenteral
• Topical
• Others

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

Click Here To Buy Your Detailed Report
https://www.futuremarketinsights.com/checkout/1260

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.